ACTRN12619001571167已完成未知
A placebo-controlled, single-blind, crossover study to assess the effects of New Zealand pine bark extract (Enzogenol®) on glycaemic responses in healthy participants
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- All
入选标准
- •18-40 years of age
- •BMI 18.5-25.0 kg/ m2
- •HbA1c < 40 mmol/ mol
- •Fasting glucose < 5.5 mmol/ L
- •Not taking any medications that include blood glucose/ sugar lowering prescriptions
- •Not pregnant or breastfeeding
- •Not allergic to pine bark extract
- •Non-smoker
- •Generally healthy and not suffering from chronic diseases or diabetes
- •Able to communicate well in English
排除标准
- •Participants were excluded from the study if they had any form of cardiovascular, metabolic diseases, digestive ailments, if they smoked, were pregnant or lactating, and if they had any known allergies to pine bark extract or were taking medications or health supplements that would influence glycaemia.
研究者
相似试验
终止
4 期
Treatment of disordered blood pressure in spinal cord injuryHypotensionSpinal cord injuryACTRN12613001021763Austin Hospital4
已完成
2 期
The effect of corticosteroids versus placebo on sleep quality in patients with advanced cancerACTRN12612000650897Mater Misericordiae Health Services Brisbane Ltd53
进行中（未招募）
1 期
A study to assess the efficacy of a vitamin D-containing ointment applied on the skin to improve wound healing in butterfly childreEUCTR2016-001967-35-ATniversitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität Salzburg15
进行中（未招募）
不适用
A placebo-controlled, double-blind, cross-over study with rupatadine 10 mg in 30 mosquito-bite allergic adult subjectsRupatadiini-antihistamiini hyttyspistoallergiassa - Rupatadiini-antihistamiini hyttyspistoallergiassamosquito-bite allergic adultsEUCTR2005-004422-50-FIJ.Uriach y Compania S.A.,30
招募中
不适用
To evaluate the efficacy andsafety of Nigellin in individuals with allergic rhinitisCTRI/2022/07/044180Sami Sabinsa Group Limited